A new generation of protection against influenza A virus in swine

First live attenuated influenza A vaccine protects pigs as early as day one

Posing a serious threat to performance, influenza A virus in swine (IAV-S) can have a widespread impact on productivity and profitability. IAV-S is one of the top three diseases affecting pigs in all phases of production,1,2 and can lead to economic losses of more than $10 per head when present with concurrent infections.3 It can also lead to subsequent respiratory infections that can impact pig performance, including mortality and culls.

Today, however, the first live attentuated influenza vaccine (LAIV) for growing pigs is here to provide game-changing protection when and where it’s needed most. Ingelvac Provenza™ from Boehringer Ingelheim offers cross-protection against multiple IAV-S strains, and decreases nasal shedding, thereby reducing transmission within a population.4

With demonstrated efficacy and safety,<sup>4</sup> and intranasal administration, Ingelvac Provenza™ from Boehringer Ingelheim stimulates immunity at the site of IAV-S infection in pigs as young as one day of age.<sup>3,6</sup> With demonstrated efficacy and safety,<sup>4</sup> and intranasal administration, Ingelvac Provenza™ from Boehringer Ingelheim stimulates immunity at the site of IAV-S infection in pigs as young as one day of age.<sup>3,6</sup>

With demonstrated efficacy and safety,4 and intranasal administration, Ingelvac Provenza™ from Boehringer Ingelheim stimulates immunity at the site of IAV-S infection in pigs as young as one day of age.3,6

With demonstrated efficacy and safety,4 as well as flexibility of timing and a method of administration that stimulates immunity at the point of natural IAV-S infection, Ingelvac Provenza™ fills an unmet need in the swine industry, and will establish a new way of thinking about influenza protection.

“Vaccinating pigs as young as one day of age provides protection before pigs are most vulnerable,”5 says Dr. Christa Goodell, DVM, MS, PhD, Dipl ACVPM, technical manager for the Boehringer Ingelheim U.S. Swine Business. Administered intranasally, Ingelvac Provenza™ provides a direct means of protection at the site of natural IAV-S infection.3,6

As the first LAIV developed for growing pigs in the United States, Ingelvac Provenza™ is a bivalent H1N1 and H3N2 vaccine that offers a new level of cross-protection against influenza A virus strains, including H1N2 and more recent H3N2,4 and has been has been evaluated to reduce virus shedding in the presence of maternal antibodies.7

“This vaccine is providing protection when it is needed most, and offers cross-protection against multiple strains of IAV-S. Ingelvac Provenza™ reduces nasal shedding when pigs are challenged with IAV-S, which reduces transmission within the population,” Dr. Goodell explains.

Ingelvac Provenza™ is currently available in a 50-dose presentation. For more information, talk to your veterinarian or visit www.IngelvacProvenza.com.

With demonstrated efficacy and safety,<sup>4</sup> and intranasal administration, Ingelvac Provenza™ from Boehringer Ingelheim stimulates immunity at the site of IAV-S infection in pigs as young as one day of age.<sup>3,6</sup> With demonstrated efficacy and safety,<sup>4</sup> and intranasal administration, Ingelvac Provenza™ from Boehringer Ingelheim stimulates immunity at the site of IAV-S infection in pigs as young as one day of age.<sup>3,6</sup>

With demonstrated efficacy and safety,4 and intranasal administration, Ingelvac Provenza™ from Boehringer Ingelheim stimulates immunity at the site of IAV-S infection in pigs as young as one day of age.3,6

Ingelvac Provenza™ 50 dose presentation photo
Disclaimer

WELCOME TO INGELVACPROVENZA.COM

Are you located within the United States of America?
ARE YOU A VETERINARIAN?

This is a required field

This website is an international information resource intended for veterinarians who are interested in information about Ingelvac Provenza™ and influenza A virus in swine.

While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that the registration status and approved product label may not be the same in different countries.

INGELVAC PROVENZA™ IS ONLY CURRENTLY LICENCED IN THE UNITED STATES OF AMERICA. Information on this website is derived from the product label in the USA.

By checking the box below, you are declaring and confirming that you are a veterinarian professional and that you have read and understood this disclaimer.

You must accept the terms and conditions and data policy to enter the website

Ingelvac Provenza is a trademark of Boehringer Ingelheim Vetmedica GmbH. © 2018 Boehringer Ingelheim Vetmedica, Inc.